Definitive Healthcare (NASDAQ:DH) Releases FY 2026 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 0.180-0.200 for the period, compared to the consensus estimate of 0.160. The company issued revenue guidance of $220.0 million-$222.0 million, compared to the consensus revenue estimate of $223.6 million. Definitive Healthcare also updated its Q3 2026 guidance to 0.040-0.050 EPS.

Analysts Set New Price Targets

Several analysts have issued reports on DH shares. Bank of America reiterated an “underperform” rating and issued a $0.70 target price on shares of Definitive Healthcare in a research note on Monday, June 29th. Robert W. Baird set a $1.10 price target on shares of Definitive Healthcare in a report on Friday, May 8th. Zacks Research upgraded Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Wall Street Zen raised Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Sunday, July 26th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Definitive Healthcare in a research report on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, three have given a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average price target of $1.88.

Definitive Healthcare Price Performance

NASDAQ DH traded down $0.01 during trading hours on Monday, reaching $0.70. 400,591 shares of the stock traded hands, compared to its average volume of 358,377. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.75 and a quick ratio of 1.75. The stock has a 50 day simple moving average of $0.78 and a two-hundred day simple moving average of $1.12. Definitive Healthcare has a 1 year low of $0.62 and a 1 year high of $4.35. The company has a market cap of $73.71 million, a price-to-earnings ratio of -0.43, a price-to-earnings-growth ratio of 11.51 and a beta of 1.35.

Definitive Healthcare (NASDAQ:DH) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. Definitive Healthcare had a positive return on equity of 4.04% and a negative net margin of 76.04%.The firm had revenue of $55.93 million for the quarter, compared to analyst estimates of $55.02 million. On average, analysts predict that Definitive Healthcare will post 0.04 EPS for the current fiscal year.

Institutional Trading of Definitive Healthcare

Several hedge funds have recently added to or reduced their stakes in DH. AQR Capital Management LLC grew its holdings in Definitive Healthcare by 56.7% in the 1st quarter. AQR Capital Management LLC now owns 590,149 shares of the company’s stock worth $1,706,000 after acquiring an additional 213,562 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Definitive Healthcare by 564.2% in the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock valued at $25,191,000 after acquiring an additional 7,404,363 shares in the last quarter. Jane Street Group LLC increased its position in Definitive Healthcare by 166.0% during the 1st quarter. Jane Street Group LLC now owns 105,114 shares of the company’s stock valued at $304,000 after purchasing an additional 65,597 shares during the period. Creative Planning increased its position in Definitive Healthcare by 41.7% during the 2nd quarter. Creative Planning now owns 28,628 shares of the company’s stock valued at $112,000 after purchasing an additional 8,428 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new position in Definitive Healthcare in the 2nd quarter worth $4,247,000. 98.67% of the stock is owned by institutional investors.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.